The Latest Breaking News from PBMs

Cuban’s Cost Plus Drugs, which he founded in 2022, similarly provides direct-to-consumer discounted pharmaceuticals.

Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly and Co. (NYSE:LLY), accusing the pharmaceutical giant of bribing medical providers to promote its most profitable drugs, including the widely used GLP-1 medications Mounjaro and Zepbound for diabetes and weight loss.

GOP spending bill proposal excludes reforms for pharmacy benefit managers (PBMs) despite bipartisan expectations.

Wegovy and Ozempic are weight loss drugs that promise to transform the treatment of obesity, heart disease and other chronic conditions that afflict millions of Americans. But while everyone agrees these drugs have the potential to transform lives, no one can agree on how best to pay for them.

Kentucky’s attorney general has expanded an opioid-related lawsuit to target another pharmacy benefit manager

Congress and President Joe Biden can address the problem of PBMs -- Pharmacy Benefit Managers -- by passing two bipartisan reforms during the current "lame duck" legislative session.

Novo Nordisk is investing $30 billion to expand production, but middlemen are pocketing 74 cents of every dollar it makes in sales.

FTC lawsuit targets major PBMs for inflating insulin prices, impacting patients and drug costs. Debate over drug pricing and PBM role in healthcare system ...

The federal government is suing some pharmacy benefit managers over a system of drug rebates that regulators say has made the price of insulin soar for patients